Blood Levels of Omega 3 and 6 across the Progression of Alzheimer's Disease

Background: Previous studies have shown that Alzheimer's disease (AD) is characterised by significant alterations of omega6 and omega3 polyunsaturated chains (PC) incorporated in phospholipids. Investigating the dynamics of PC changes during the natural history of AD, in the brain as well as in the blood, is key for highlighting the role of fatty acids metabolism as therapeutic target. Current advances in disease progression modelling (DPM) allow estimating the long term temporal trajectory of AD biomarkers from collections of individual's observations acquired in clinical trials. Furthermore, these models enable the automatic staging of patients according to the measured biomarkers profile. In this study we leverage on DPM to model the changes of blood omega6/omega3 ratios across the natural evolution of AD estimated in clinical data.